EGFR and non-small cell lung carcinoma: The RAMOSE phase 2 trial, enrolling TKI-naïve EGFR-mutated NSCLC patients, showed a median PFS of 24.8 months for the combination therapy versus 15.6 months in the osimertinib-treated group, with a manageable safety profile for the combination [236].